Waverley Pharma Inc.
WAVE.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,959.58% | 729.98% | 181.06% | 11.22% | -87.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,959.58% | 729.98% | 181.06% | 11.22% | -87.01% |
| Cost of Revenue | 740.70% | 304.88% | 125.75% | -24.07% | -72.57% |
| Gross Profit | 1,784.13% | 2,301.14% | 331.28% | 156.19% | -121.02% |
| SG&A Expenses | 18.56% | -24.40% | -37.93% | -43.26% | -34.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.30% | 9.75% | -0.37% | -22.62% | -34.03% |
| Operating Income | 75.62% | 73.38% | 45.51% | 33.52% | 13.24% |
| Income Before Tax | 83.82% | 82.41% | 66.99% | 57.69% | -99.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 83.75% | 82.41% | 66.99% | 57.69% | -99.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 83.75% | 82.41% | 66.99% | 57.69% | -99.98% |
| EBIT | 75.62% | 73.38% | 45.51% | 33.52% | 13.24% |
| EBITDA | 77.16% | 70.07% | 38.32% | 29.36% | 9.59% |
| EPS Basic | 83.44% | 82.14% | 66.67% | 57.57% | -101.33% |
| Normalized Basic EPS | 72.22% | 70.54% | 42.31% | 27.27% | -13.68% |
| EPS Diluted | 86.26% | 75.14% | 50.92% | 47.53% | -73.33% |
| Normalized Diluted EPS | 72.22% | 70.54% | 42.31% | 27.27% | -13.68% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |